You have the power to make a difference 

Thank you for sponsoring our 2008 CaNIOS annual meeting. The support we receive from you is critical to the success of our conference. Your sponsorship is greatly appreciated by all of our members, patients and researchers.

Actelion www.actelion.com/ 

Actelion Ltd is a biopharmaceutical company with corporate headquarters in Allschwil/Basel, Switzerland, that focuses on the discovery, development and commercialization of innovative treatments to serve high unmet medical needs.

Founded in late 1997, Actelion is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood stream. The company currently has two approved drugs on the market.

Actelion’s lead product, Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension (PAH), a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. The second marketed product, Zavesca®, was in-licensed from Oxford GlycoSciences. Zavesca® is the only approved oral treatment for Type 1 Gaucher’s disease, a rare debilitating metabolic disorder.

Actelion aims to combine the innovation, entrepreneurial spirit and flexibility of biotech with the financial, risk management, regulatory and commercial discipline of a large pharmaceutical company. In implementing this strategy, the company builds upon its proven ability to discover new compounds and to move compounds from research through development to commercialization.

Amgen Canada Inc. www.amgen.com/  

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about our pioneering science and our vital medicines

Bristol-Myers Squibb Canada www.bms.com/ 

(The following are excerpted from BMS's web site)

Bristol-Myers Squibb is a leading provider of medicines to fight cancer, cardiovascular and infectious diseases -- including HIV/AIDS -- and serious mental illness. In our world-class research and development facilities -- located in New Jersey, Connecticut and elsewhere around the globe -- we’re looking for new and better treatments for cancer, diabetes, HIV/AIDS and other serious illnesses and conditions. Augmenting our internal R&D capabilities, Bristol-Myers Squibb has an extraordinary history of successful partnerships to develop and deliver important new medicines to people who need them worldwide.

Bristol-Myers Squibb's other businesses also meet significant health needs of people worldwide. Mead Johnson Nutritionals, known for its Enfamil® line of infant formula, is a leader in providing infant and child nutrition. ConvaTec offers high-quality ostomy and wound therapeutics products and services.

Realizing our mission and excelling as a company require us to make every effort to build a diverse and motivated work force composed of leaders at all levels across the organization. To encourage our employees to achieve their fullest potential, we are committed to developing their leadership and professional skills as well as helping them maintain an appropriate balance between their personal and professional lives. We have been consistently honored by National Association of Female Executives as one of the Top 30 Companies for Executive Woman; and by Working Mother magazine as one of the 100 Best Companies for Working Mothers.

Pursuing our mission also means working hard to expand people’s access to quality medicines and health care. We’re striving toward this goal through public/private partnerships like SECURE THE FUTURE®, our pioneering $150 million HIV/AIDS initiative in southern and western Africa, and through programs like the Patient Assistance Foundation and Together Rx Access. In addition, our company -- together with the Bristol-Myers Squibb Foundation -- supports numerous health and education projects, and donates our medicines and other products to people in need in the U.S. and abroad. In 2005, we committed more than $750 million in products and financial support to our wide-ranging philanthropic efforts. According to The Chronicle of Philanthropy, we are among the top U.S. companies for corporate charitable giving. In these and indeed in all of our company’s endeavors, we are guided by the values expressed in the Bristol-Myers Squibb Pledge.